155 related articles for article (PubMed ID: 10967992)
1. Radiation doses to patient's relatives following radioiodine therapy.
Sulaiman BT; Clarke SE
Med J Malaysia; 1996 Mar; 51(1):131-3. PubMed ID: 10967992
[TBL] [Abstract][Full Text] [Related]
2. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
3. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
4. [Guidelines for radio-iodine (131I) therapy in Graves' disease and thyroid cancer].
Mori Y; Kusakabe K; Ikekubo K; Ishikawa N; Nakada K; Kanaya S; Misaki T; Yokoyama K; Kubo A; Higashi T; Itou K; Noguchi Y; Tsuchimochi S; Togawa T;
Kaku Igaku; 2005 Feb; 42(1):17-32. PubMed ID: 15794118
[TBL] [Abstract][Full Text] [Related]
5. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
6. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
7. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism.
Jönsson H; Mattsson S
Radiat Prot Dosimetry; 2004; 108(2):107-14. PubMed ID: 14978290
[TBL] [Abstract][Full Text] [Related]
8. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
9. [Exhalation of I-131 after radioiodine therapy (RIT): time dependence and chemical form].
Schomäcker K; Fischer T; Eschner W; Gaidouk MI; Schicha H
Nuklearmedizin; 2001 Feb; 40(1):15-22. PubMed ID: 11373934
[TBL] [Abstract][Full Text] [Related]
10. Radioactive iodine therapy in Graves' hyperthyroidism.
Sankar R; Sripathy G
Natl Med J India; 2000; 13(5):246-51. PubMed ID: 11190053
[TBL] [Abstract][Full Text] [Related]
11. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
Baczyk M; Junik R; Ziemnicka K; Sowiński J
Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
[TBL] [Abstract][Full Text] [Related]
12. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
13. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
[TBL] [Abstract][Full Text] [Related]
14. [Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in their homes].
Wellner U; Eschner W; Hillger HW; Schicha H
Nuklearmedizin; 1998 May; 37(3):113-9. PubMed ID: 9604232
[TBL] [Abstract][Full Text] [Related]
15. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
16. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
17. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma.
Van Nostrand D; Atkins F; Yeganeh F; Acio E; Bursaw R; Wartofsky L
Thyroid; 2002 Feb; 12(2):121-34. PubMed ID: 11916281
[TBL] [Abstract][Full Text] [Related]
18. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
Marriott CJ; Webber CE; Gulenchyn KY
Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
[TBL] [Abstract][Full Text] [Related]
19. Airway complication occurring during radioiodine treatment for Graves' disease.
Kinuya S; Yoneyama T; Michigishi T
Ann Nucl Med; 2007 Aug; 21(6):367-9. PubMed ID: 17705018
[TBL] [Abstract][Full Text] [Related]
20. Radiation safety considerations for post-iodine-131 hyperthyroid therapy.
Culver CM; Dworkin HJ
J Nucl Med; 1991 Jan; 32(1):169-73. PubMed ID: 1988627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
